Physician profile
Michael T Stechison
NPI 1588795934
$1,888.91
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.78 · 2020: $55.63 · 2022: $42.05 · 2023: $1,203 · 2024: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $865 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $554 · Food and Beverage: $338 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $864.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $554.40 |
| Food and Beverage | $338.45 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,129.92 | 2023 | Stealth Autoguide System, Strata, Midas Rex |
| Spineology INC. | $567.87 | 2020-2024 | Optimesh Expandable Interbody Fusion System |
| Depuy Synthes Sales INC. | $69.23 | 2020-2023 | Matrixneuro |
| Integra Lifesciences Corporation | $31.19 | 2020-2023 | Duraseal Exact Spinal Sealant System, Codman Certas, Cusa Clarity |
| Stryker Corporation | $21.74 | 2022 | |
| Baxter Healthcare | $20.31 | 2022 | |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Welireg |
| Medtronic USA, INC. | $15.78 | 2019 | |
| Hydrofera LLC | $14.78 | 2023 | Hydrofera Blue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$636,487.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stechison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.